NEW YORK – August 27, 2025 – The Cardiovascular Research Foundation® (CRF®) is excited to announce the late-breaking clinical trials and science set to be presented at TCT® 2025, the annual scientific symposium of CRF® and the world’s premier educational meeting specializing in interventional cardiovascular medicine. This year’s conference will take place October 25–28 at the Moscone Center in San Francisco, bringing together top experts, innovators, and clinicians from around the globe.
For more than 30 years, TCT® has served as a cornerstone for advancing cardiovascular care, showcasing transformative research and fostering collaboration across disciplines. Each year, the symposium delivers pivotal data that shapes clinical practice and enhances outcomes for patients with heart and vascular disease.
Late-breaking clinical trials and science are among the most anticipated sessions, offering first looks at novel therapies, devices, and techniques. This year, 28 cutting-edge studies will be presented, focusing on the safety and efficacy of minimally invasive procedures, emerging pharmaceuticals, and breakthrough technologies aimed at preventing and treating cardiovascular conditions.
These high-impact findings will be featured in the main program and spotlighted during dedicated press briefings on Sunday, October 26, Monday, October 27, and Tuesday, October 28.
Sunday, October 26, 2025
One-Year Results of the SELUTION DeNovo Trial Comparing a Strategy of PCI with a Sirolimus-eluting Balloon and Provisional Stenting Versus Systematic DES Implantation to Treat DeNovo Coronary Lesions
Christian M. Spaulding
Sirolimus-Eluting Balloon Versus Repeat Drug-Eluting Stenting or Balloon Angioplasty for In-stent Restenosis
Donald Cutlip
Randomized Comparison of Intravascular Lithotripsy vs. Cutting Balloon Treatment in Calcified Coronary Artery Disease – The Short-CUT Trial
Suzanne J. Baron
A Randomized, Multicenter, Non-Inferiority Comparison of Intravascular Lithotripsy and Super-High-Pressure Non-Compliant Balloons for Treatment of Calcified and Refractory Coronary Lesions - The VICTORY Trial
Randomized Controlled Trial of Mechanical Thrombectomy with Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Results from STORM-PE
Robert A. Lookstein
Three-Year Outcomes of the LIFE-BTK Randomized Controlled Trial Evaluating the Esprit™ BTK Drug-Eluting Resorbable Scaffold for Treatment of Infrapopliteal Lesions
Sahil A. Parikh
Short-Term Anticoagulation Versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure
Josep Rodés-Cabau
Evaluating Real-World Outcomes of the EVOQUE Valve in Early Commercial Experience from the STS/ACC TVT Registry
Raj Makkar
Lessons Learned from 800+ Patients Treated with Tricuspid TEER: Update from the TRILUMINATE Pivotal Trial
Jonathan G. Schwartz
Monday, October 27, 2025
Defining the Prevalence of Valvular Heart Disease in Older Americans: The PREVUE-VALVE Study
David J. Cohen
Long-Term Follow-up of the PARTNER 3 Low-Risk Randomized Trial: Seven-Year Clinical and Echocardiographic Outcomes
Michael J. Mack
Tendyne Transcatheter Mitral Valve System in Patients with Severe Mitral Annular Calcification: One-year Outcomes from the SUMMIT Severe MAC Cohort
Paul Sorajja
Percutaneous Transseptal Transcatheter Mitral Valve Replacement using a Dedicated Balloon Expandable Valve: 1 Year Outcomes from the ENCIRCLE Trial using the SAPIEN M3
David Daniels
Long Term Clinical Outcomes in Patients Treated with the Bioadaptor Compared with a Contemporary Drug Eluting Stent: The INFINITY-SWEDEHEART Randomized Trial
David Erlinge
Comparison of Drug-Coated Versus Conventional Balloons for Treatment of Side Branches of Bifurcation Lesions: The OCVC-BIF Study
Takayuki Ishihara
Sirolimus-Eluting Iron Bioresorbable Scaffold in Coronary Artery Disease: Two-Year Results of IRONMAN-II Randomized Controlled Trial
Lei Song
Drug-Coated Balloon Angioplasty with Rescue Stenting Versus Intended Stenting for the Treatment of DeNovo Coronary Artery Lesions: 3-Year Clinical Outcomes of the REC-CAGEFREE I Trial
Chao Gao
Percutaneous Coronary Angioplasty Versus Coronary Artery Bypass Grafting in the Treatment of Unprotected Left Main Stenosis: 10-year Mortality Outcomes from the Randomized NOBLE Trial
Evald H. Christiansen
Tuesday, October 28, 2025
Percutaneous Coronary Intervention of Native Coronary Artery versus Saphenous Vein Graft in Patients with Prior Coronary Artery Bypass Graft Surgery (PROCTOR): A Multicenter, Open-label, Randomized Trial
Ruben de Winter
Effects of Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator as an Ajunct to Primary PCI in Patients with STEMI and Large Thrombus Burden: A Randomized, Double-Blind, Placebo-Controlled Trial
Shamir R. Mehta
Immediate Instantaneous Wave-Free Ratio Guided Versus Deferred Cardiac Magnetic Resonance Imaging Guided Revascularization of Non-Culprit Lesions in Patients with Acute ST-Elevation Myocardial Infarction: A Randomized Superiority Trial
Robin Nijveldt
Stratified Treatment of Myocardial Infarction with Non-Obstructive Coronary Arteries: The PROMISE Trial
Rocco Antonio Montone
Supraflex Cruz versus Xience in Patients with Diabetes and Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Results from the TUXEDO-2 Randomized Trial
Upendra Kaul
iFR Versus Angiography-Guided CABG: 3-Year Results of the iCABG Randomized Trial
Rasa Ordiene
Randomized Comparison of the Supraflex CruzTM vs. SYNERGYTM Drug-Eluting Stents: The Multivessel TALENT Randomized Trial
Patrick W. Serruys
A Prospective, Randomized Clinical Trial of Hemodynamic Support with a Novel Developed pVAD Versus IABP in Patients Undergoing High-Risk Percutaneous Coronary Intervention
Rui Wang
AI-Enabled ECG Interpretation in STEMI: Findings from a Multicenter U.S. Registry
Timothy D. Henry
The Effectiveness and Safety of a Planned Investment Procedure in High-Risk Chronic Total Occlusions - The INVEST CTO Single Arm Study
Anja Oksnes
Media are invited to attend TCT® and can apply for media credentials at: https://www.tctconference.com/press-registration.
Receive updates on X at https://x.com/TCTConference and https://x.com/crfheart.
About CRF® and TCT®
The Cardiovascular Research Foundation® (CRF®) is a global leader in interventional cardiovascular medicine, driving innovation, spearheading groundbreaking research, and transforming education in the field. Through its relentless pursuit of excellence, CRF® not only accelerates medical breakthroughs but also equips healthcare professionals with the tools and knowledge necessary to enhance survival rates and elevate the quality of life for millions worldwide. CRF®’s centers of excellence include the CRF® Skirball Center for Innovation, CRF® Clinical Trials Center, CRF® Center for Education, CRF® Digital, TCTMD®, and Structural Heart: The Journal of the Heart Team.
Transcatheter Cardiovascular Therapeutics® (TCT®) is the annual scientific symposium of CRF® and the world’s premier educational meeting specializing in interventional cardiovascular medicine. Anchored in a legacy spanning over three decades, TCT® is a world-class educational experience featuring disruptive innovation, scientific breakthroughs, expert-led tutorials, hands-on training, and ample opportunities for networking and collaboration.
For more information, visit www.crf.org and www.tctconference.com.